Plain-language medicine for patients and families: guides, explainers on how the system works, and care in Fresno and the Central Valley.
October 10, 2026 edition · Developments from September 25 to October 10
Latest record
Published · Source published · Event
California continues state-funded maintenance dialysis for restricted-scope members
Federal matching treatment and state coverage are different questions.
DHCS describes state-funded continuation of non-emergency maintenance dialysis and related transportation for restricted-scope Medi-Cal members after a federal financing review. Coverage policy and billing implementation are being updated. Patients should confirm arrangements with their dialysis team rather than interpret a federal payment change as an instruction to miss treatment.
California agencies clarify home-visiting referrals
The September 30 letter describes coordination, not a new mandate.
DHCS, CDPH and CDSS issued best-practice guidance on connecting pregnant and postpartum Medi-Cal members with home-visiting programs. DHCS says the letter clarifies existing requirements and referral coordination rather than creating new requirements.
Request for information · Source published · Event · Deadline
FDA seeks input on ibogaine research
The request concerns research design and safety; it is not an approval.
The FDA’s October 5 request for information asks for input on developing ibogaine research, including the evidence needed for early clinical trials and the management of safety risks. Comments are due November 20.
The announcement does not establish that ibogaine is approved, effective for a particular condition or appropriate for unsupervised use. A research proposal still needs the applicable regulatory authorization, ethical oversight and clinical safeguards. Keep the distinction between promising research questions and demonstrated patient benefit visible when discussing addiction-treatment innovation.
FDA approves a pulmonary valve designed for later expansion
The design may accommodate growth, but lifetime outcomes are not yet established.
The FDA’s October 1 approval covers the Autus Size-Adjustable Valve, a surgically implanted pediatric pulmonary valve designed to be enlarged later using a catheter-based balloon procedure. The device can expand from 13 to 22 millimeters.
The reported study enrolled 62 patients, with six-month data available for 60. Experience with actual valve expansion was much smaller. The approval evidence therefore should not be presented as proof that every child will avoid later surgery or that lifelong durability is known. The FDA also reported frame fractures and leaflet-motion findings in the study. Families should discuss the specific anatomy, alternatives, follow-up and uncertainty with the treating congenital-heart team.
A first FDA-approved treatment targets peripheral thyrotoxicosis in MCT8 deficiency
The indication is narrower than a cure for the whole disorder.
The FDA announced approval of Emcitate, or tiratricol, on September 28 for peripheral thyrotoxicosis associated with MCT8 deficiency. This rare disorder affects thyroid-hormone transport and can have major developmental and neurologic consequences.
The approval should be described using its actual treatment target. It does not establish reversal of every neurologic or developmental effect of MCT8 deficiency. Treatment decisions, monitoring and expectations belong with clinicians experienced in the condition and the approved prescribing information.
FDA approval adds an option for refractory HSV lesions in certain adults
The population is immunocompromised adults with treatment-resistant mucocutaneous disease.
The FDA describes Hovilpri, or pritelivir, as a treatment for refractory mucocutaneous herpes simplex virus infection in immunocompromised adults. This is a specific clinical population, not a general replacement for familiar HSV treatments and not a cure for latent infection.
In the reported randomized, open-label study of 101 patients, lesion healing by day 28 occurred in 63% of the pritelivir group and 34% of the comparator group. That result should be read with the trial design, eligibility criteria, adverse effects and drug interactions. Patients should not change an existing antiviral regimen based on an approval headline.
FDA expands manufacturers’ options for salt substitutes
A food-standard change does not guarantee lower sodium in every product.
The FDA’s October 9 final rule permits salt substitutes in foods covered by 139 standards of identity. It gives manufacturers additional formulation options; it does not require every affected product to reduce sodium.
Consumers still need to compare the actual label. A regulatory allowance for an ingredient is also different from individualized dietary advice. People with medical conditions or medicines that affect potassium handling should discuss potassium-containing salt substitutes with their clinician before making substantial changes.
Sprouting-seed recall expands during a Salmonella investigation
Check the current product and lot list before using seeds for home sprouting.
The FDA’s October 9 update reports 32 illnesses and three hospitalizations in the Salmonella investigation linked to sprouting seeds, with no deaths reported. Listed cases were in six states; the distribution record was broader. California distribution should not be mistaken for a confirmed California illness.
The investigation identifies seed lot W4105 and several recall announcements. Consumers and retailers should use the FDA’s live recall table to match the brand, lot and product rather than rely on a shortened news summary. Do not eat or grow sprouts from a recalled seed product. Preserve the update date with these figures because outbreak counts and recall lists can change.
NEST launches with newborn and postpartum supplies
The October 9 launch took place in West Virginia; local availability needs confirmation.
HHS launched the Newborn Essentials Support Toolkit program in Morgantown, West Virginia, on October 9. The program supplies a one-time package of newborn and postpartum items through maternity-care partners. HHS reports a $5 million implementation award to the CDC Foundation.
The launch does not establish that kits are available at every hospital or in Fresno. Families should ask a participating maternity-care organization about local distribution. Earlier recipient surveys describe reported satisfaction and financial or emotional relief; they should not be presented as controlled evidence that the program improves clinical outcomes.
Award announced conditional · Source published · Event
Federal falls-prevention awards include a California organization
The announced funding is spread over three years and remains subject to future funding.
HHS announced up to $27.8 million for falls-prevention work on October 9. The three-year awards include Partners in Care Foundation in San Fernando, California, listed for approximately $1.83 million. The funding supports screening, referrals and community prevention programs.
An announced award is different from money already spent or a service available in every county. The California recipient should not be relabeled as a Fresno award. Older adults and caregivers can use the announcement to ask local health and community organizations about established falls-risk assessment and prevention services, while local availability is verified separately.
Manufacturer reported fda approval · Source published · Event
Teva announces approval of monthly subcutaneous olanzapine
The new formulation is for adults with schizophrenia.
Teva announced October 9 that the FDA approved Weltruza, a once-monthly subcutaneous extended-release olanzapine formulation for adults with schizophrenia. The company says US availability is expected in the coming weeks, which should not be restated as confirmed local availability tonight.
The announcement includes substantial safety information, including metabolic effects and the increased mortality risk in elderly patients with dementia-related psychosis; the product is not approved for that condition. A formulation change does not make olanzapine risk-free or establish that it is the best choice for every patient. Use current prescribing information and the treating clinician’s assessment before considering a switch.
Company recall posted by fda · Source published · Event
One RAPTURE Preworkout lot is recalled for DMAA
The FDA-posted company notice identifies lot 260327-4.
Leader Formulas recalled one lot of RAPTURE Preworkout after testing found DMAA. The company announcement is dated October 6 and the FDA posting October 7. The notice identifies lot 260327-4 in 450-gram containers.
The recall instructions tell consumers to stop using the affected product and return it to the place of purchase. DMAA can raise blood pressure and is associated with serious cardiovascular risks. Match the product and lot against the official notice; this announcement should not be generalized into a recall of every preworkout supplement.